Research on reforming post-management of pharmaceuticals

Initiated

The KIHASA will conduct the research, ordered by the Ministry of Health and Welfare (MOHW)…a reporting session was held on May 29th

The government has initiated research on developing a comprehensive reform of post-insurance management of pharmaceuticals.

 

This research was part of the 2nd Comprehensive NHI Plan, announced earlier this year.

 

According to industry sources on May 29th, a policy initiative reporting session was held to announce the start of the research on post-insurance management of pharmaceuticals.

 

As part of the 2024 initiative plan for the 2nd Comprehensive NHI plan, which was announced last month, policy initiative research will be conducted to develop a comprehensive reform of post-insurance management of pharmaceuticals.

 

This plan aims to effectively manage the cost of pharmaceuticals as part of a mid-to-long-term strategy.

 

The research will include the current state of the post-insurance management program, accomplishments, comparisons to foreign countries, and suggestions for improving the program to suit South Korean settings.

 

The MOHW announced that the research will start in May and be completed by December.

 

The Korea Institute for Health and Social Affairs (KIHASA) will conduct the research under a contract with the MOHW.

 

"The research aims to develop a comprehensive reform of the post-insurance management of pharmaceuticals, including the Health Insurance Review and Assessment Service (HIRA)’s reevaluation of reimbursement appropriateness and the National Health Insurance Service (NHIS)’s Price-Volume Agreement (PVA) program," a government official explained.

 

“Therefore, the MOHW, the HIRA, and the NHIS officials have joined the reporting session.” Earlier this year, there were talks of a possible reevaluation of comparisons to foreign pharmaceutical pricing following the research on the comprehensive measures for post-insurance management of pharmaceuticals.

 

However, it appears that there are plans to separately pursue the reevaluation of comparisons to foreign pharmaceutical pricing this year.

 

When the research report is available at the end of this year, there will be a discussion on systemization next year.